Atlas Trials

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)

Clinical trial NCT01914367 · COMPLETED

Trial details

NCT number
NCT01914367
Sponsor
University Hospital, Ghent
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Infection With Human Papillomavirus
Start date
2013-06-25
Primary completion
2015-09-23
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.